What Гразакс Treats: Main Uses and Benefits

Гразакс is applied as a type of disease-modifying treatment for hay fever caused specifically by grass pollen, relevant in patients with confirmed sensitivity and clinically relevant symptoms of allergic rhinitis and/or conjunctivitis. The treatment is indicated as immunotherapy for grass pollen-induced allergic rhinitis with or without conjunctivitis. It is commonly used when symptoms become more disruptive during seasonal flare-ups and when patients seek therapeutic support that goes beyond temporary relief.

This treatment helps manage the major symptomatic clusters, including nasal symptoms (such as frequent sneezing, profuse runny nose, and congestion) and ocular symptoms (including itchy, watery, and red eyes). The therapeutic approach is relevant for helping to achieve a sustained reduction in hypersensitivity over time, providing support that generally helps ease the overall symptom burden.

Quick Facts on Therapeutic Benefit

Quick Fact:	Description
Relevant for	Grass Pollen Allergy (hay fever with clinically relevant symptoms)
Primary Goal	Assisting with maintaining functional stability during the symptomatic phase
Symptom Focus	Managing symptom clusters that create noticeable physiological strain (rhinoconjunctivitis)

Who Can and Cannot Use Гразакс?

Eligibility for Гразакс (Timothy grass pollen allergen extract) is strictly defined by regulatory documents, focusing on age, underlying conditions, and immune status. The medicine is approved for use in adults, adolescents, and children from 5 years of age who have clinically relevant grass pollen-induced allergic rhinitis and/or conjunctivitis, confirmed by positive diagnostic tests.

---

Absolute Contraindications

Treatment is contraindicated and must not be used in specific patient populations, including:

• Patients with severe, unstable, or uncontrolled asthma.
• Individuals with a history of eosinophilic esophagitis.
• Those with malignant disease or systemic diseases affecting the immune system (e.g., autoimmune or immunodeficiency diseases).
• Known hypersensitivity to the active ingredient or any excipients.

---

Use Restrictions and Limitations

Eligibility is further restricted for certain populations, often due to a lack of established clinical data:

• Not recommended for use in children under 5 years or adults 65 years or older.
• Initiation of treatment is not recommended during pregnancy or lactation.
• Patients must temporarily stop treatment (for 7 days) following oral surgery or in the presence of severe oral inflammation.

Interactions with other medicines and products

Гразакс (Grazax) is an allergen immunotherapy product, and its official interaction profile, as documented in regulatory sources, differs significantly from that of systemically metabolized medicines. Interactions are primarily focused on pharmacodynamic effects and the condition of the sublingual administration site.

---

Documented Pharmacodynamic and Local Interactions

Interaction Type	Description (Official Regulatory Statement)
Allergen Immunotherapy	Concomitant use with other allergen immunotherapy products may increase the risk of systemic or local adverse reactions.
Oral Mucosa Status	Treatment must be temporarily stopped following oral surgical procedures (including tooth extraction) or in the presence of severe oral inflammation or wounds.

---

Status of Other Interactions

Official regulatory documents do not document the following interaction types for Гразакс, as its therapeutic effect is immunological rather than systemic:

• Formal Contraindications: No combinations with other medicinal products are formally classified as absolutely contraindicated due to drug-drug interaction risk.
• Metabolic Interactions: No clinically relevant interactions involving CYP450 enzymes or drug transporters (e.g., P-gp) are documented or anticipated.
• Food, Alcohol, Supplements: No specific restrictions or interactions with food, alcohol, or herbal products are documented.

The Mechanism of Immunological Tolerance Induction

The core mechanism involves modulation of the adaptive immune system through chronic exposure to the standardized Timothy grass pollen extract, acting directly on the differentiation and expansion of Regulatory T cells (Tregs). This T-cell modification results in the systemic modulation of hypersensitivity toward the allergen.

️ Antibody Reprogramming and Effector Constraint

This T-cell modulation drives B cells to alter antibody production, resulting in the suppression of allergic Immunoglobulin E (IgE) synthesis and the elevation of protective Immunoglobulin G4 (IgG4) blocking antibodies. The circulating IgG4 then sequesters the grass pollen antigen, functionally constraining the activation and degranulation of mast cells and basophils, which limits downstream mediator release.

⏳ Time-Dependent Pharmacological Constraint

The mechanism is inherently time-dependent, requiring a prolonged period of exposure to generate a critical mass of Tregs and sufficient levels of protective IgG4 antibodies. This time requirement reflects the necessity of a prolonged period for the establishment of cellular changes in the adaptive immune system.

General Principles of Use

Гразакс is a prescription treatment administered through the sublingual route, meaning the medicine is placed under the tongue for absorption. The treatment is based on a fixed, once-daily schedule that requires continuous use over an extended period. This usage pattern is designed to support long-term immunological tolerance by maintaining consistent exposure to the standardized allergen extract.

Official Dosing and Administration

Usage Entity	Standard Instruction
Dose	One 75,000 SQ-T oral lyophilisate (tablet) once daily. This fixed dose serves as both the starting and maintenance regimen.
Frequency and Duration	Taken daily, year-round. The recommended duration of continuous use is 3 consecutive years to achieve the documented disease-modifying effect.
Timing	Treatment must be initiated at least 4 months before the expected start of the grass pollen season.
Age Range	Approved for use in children aged 5 years or older, adolescents, and adults, using the same single daily dose.

Procedural Instructions

The tablet must be placed under the tongue immediately upon removal from the blister and allowed to dissolve completely. It is necessary to avoid swallowing for approximately one minute after placement. To ensure proper administration, food and drink should not be consumed for the subsequent 5 minutes following the dose. It is required that the very first dose of the treatment must be taken under the supervision of a healthcare professional. If use is interrupted for longer than 7 days, consultation with a specialist is recommended before resumption.

Overview of Studies for Гразакс (Grazax)

This section summarizes the official clinical research evidence for Гразакс, focusing on the types of studies regulators examine, the populations evaluated, and the overall scope of the data. The information here reflects only what research has explored and reported, and is not a guide for treatment or use.

---

Evidence for Use in Grass Pollen-Induced Allergic Rhinitis and Conjunctivitis

The primary research used large, international randomized, double-blind, placebo-controlled clinical trials (RCTs). These studies were designed to evaluate differences in observed patterns between individuals receiving the active compound and those receiving an inactive placebo. These findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level, such as patient-reported total symptom scores (TRSS) and total rescue medication scores (TRMS) tracked throughout the grass pollen season.

The findings from the initial pivotal trials describe patterns observed only within the specific populations studied, which typically involved adults and children (ages 5 and older) with moderate-to-severe symptoms. The primary research design centered on comparisons against a placebo; evidence comparing Гразакс directly against other active symptomatic treatments is limited.

---

Evidence in Patients with Concomitant, Controlled Asthma

Research has explored the use of Гразакс in a specific subgroup of patients: those who have grass pollen allergic rhinoconjunctivitis along with mild-to-moderate, well-controlled concomitant asthma. Studies monitored outcomes describing episodic or acute changes in asthma symptom scores and the use of asthma-specific rescue medication, often as secondary endpoints.

The specific pre-defined primary measurement in a dedicated prevention study was not reported to have been achieved. Therefore, the available research focuses on patterns observed in secondary outcomes. Data for certain groups remain insufficient, as the existing trials generally excluded patients with severe or uncontrolled asthma.

---

Long-Term Research and Durability of Study Findings

The evidence base includes long-term studies and follow-up periods that extended beyond the initial three-year treatment phase. Extended follow-up studies described measurements of symptoms and medication scores that continued to be tracked for up to two years after the treatment was stopped. This type of research has explored short-term symptom changes, aiming to provide context regarding the sustained nature of the observed patterns. Long-term effects are not fully established beyond the total five-year observation window, and research is ongoing to gather further observations.

---

Areas of Research Uncertainty and Study Limitations

A significant limitation is the nature of the primary research comparator: the largest, core studies used an inactive placebo. Research exploring direct comparisons against other active symptomatic treatments is limited. Furthermore, certainty remains low because research is limited for populations that were specifically excluded from the pivotal trials, such as patients with very severe or unstable allergy symptoms. Research provides context but not individual predictions, as study results reflect the specific group patterns and conditions under which they were conducted.

Key Studies & References

1. Australian public assessment for Grazax - Allergenic extract of standardised grass pollen extract (TGA AusPAR)

Common questions about Гразакс (FAQ)

---

Q: If I forget my dose, should I take two the next day?

If a dose is missed, official product information advises that it should be taken later the same day. However, it advises against taking a double dose on the following day to compensate for the missed dose. If treatment is interrupted for a period longer than seven days, a patient should consult a healthcare professional before resuming the daily regimen.

---

Q: When exactly is the first dose of Grazax supposed to be taken?

Regulatory documents indicate that treatment should be initiated at least four months before the expected start of the grass pollen season. Furthermore, the very first dose is required to be taken under the supervision of a healthcare professional. Beyond these specific criteria, official information does not place restrictions on the specific time of day for administration.

---

Q: What are the most common side effects of Grazax?

The most commonly reported effects from clinical studies are localized allergic reactions in the mouth and throat. These classified reactions include oral pruritus (itching of the mouth), oedema mouth (swelling of the mouth), and pharyngeal pruritus (throat irritation). According to official product information, these effects are typically mild to moderate and generally decrease with continued, long-term use.

---

Q: Does the treatment work for all types of allergies, or only grass pollen?

Official regulatory documents indicate that this medicine is an allergen extract specifically used for immunotherapy directed at grass pollen-induced allergic rhinitis and conjunctivitis. Its indicated use is specifically for this condition.

---

Q: How do I know if Grazax is actually working for me?

Official studies indicate that the expected clinical effect is associated with a reduction in grass pollen allergy symptoms and a decreased use of rescue allergy medication during the pollen season. Regulatory documents state that if a patient does not observe relevant symptom improvement during the first pollen season, there is no indication for continuing the treatment.

---

Q: Does this medicine need to be stored in the refrigerator?

Official storage instructions mandate that the medicine be kept in a cool, dry place, generally below 25 C or not above 30 C in its original carton to protect it from light. The official product information does not require the medicine to be stored in a refrigerator.

---

Q: Is Grazax supposed to be taken year-round, or only during the grass season?

Official product labeling requires the treatment to be taken daily, year-round. This continuous, daily use is necessary for the recommended duration of three consecutive years, including the intervals between the grass pollen seasons, to support the intended long-term immunological benefit.

Official Storage and Disposal Instructions

Regulatory documentation mandates specific conditions to ensure the integrity of the Гразакс oral lyophilisate. The medicine must be stored in a cool, dry place, generally below 25 C or not above 30 C. To maintain stability and prevent degradation, the individual blister units must remain in the original carton to protect them from light.

Requirement	Official Rule
Temperature	Store below 25 C / Not above 30 C
Handling	Use immediately after opening the blister
Child Safety	Keep out of the sight and reach of children
Disposal	Do not throw away via wastewater or household waste

Disposal must adhere to official guidelines; patients are instructed to consult a pharmacist regarding the proper method for discarding any unused or expired product. The sensitive nature of the oral lyophilisate also requires immediate use upon opening the individual blister unit.